Pulmonary vein isolation (PVI) has been established as the mainstay of interventional management of atrial fibrillation, as has the utility of cryoablation as one of two standard thermal techniques for achieving PVI. 1 The efficacy of cryoballoon ablation is known to be comparable to radiofrequency ablation, however novel technologies within the realm of contemporary cryoablation have yet to be explored. 2,3 Ellenbogen et al. report the results of an international multicenter, open-label, prospective, single-arm study on the safety and performance of PolarX™ (BosSci), a new cryoballoon system for treatment of paroxysmal atrial fibrillation. 3 Compared to the current standard of care Medtronic cryoablation system, the Boston Scientific system differs in its design. The FlexCath™